Retatrutide has no regulatory approval from the MHRA, EMA, or any global authority as of 2024
It does not promise future results
GLP-1 receptor agonists act primarily by enhancing postprandial insulin secretion and suppressing glucagon release, leading to improved glycemic control (8)
S10B-S10C) nor showed signs of inflammation, fibrosis, or liver failure (Fig
It belongs to a wider set of peptides moving through longevity and biohacker circles, including BPC-157, Cerebrolysin, Semax, Selank, Dihexa, P21, and the neurotrophic factors BDNF and klotho, whose human cognitive evidence ranges from thin to absent and which I reviewed in detail here
Such mitochondrial resilience makes it a candidate for inclusion in experimental energy optimization stacks